Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Eleva Gmbh

Clinical trials sponsored by Eleva Gmbh, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New hope for rare kidney disease? first human trial of CPV-104 begins Results expected Nov 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

New hope for rare kidney disease? first human trial of CPV-104 begins

Disease control Recruiting now

This study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receivin…

Phase 1 • Sponsor: eleva GmbH • Aim: Disease control

Last updated Aug 02, 2026 00:00 UTC